Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Longeveron announces updated results of ELPIS II, the Company's trial evaluating its stem cell therapy in HLHS.
Covered in this story
Call it yourself
No calls on $LGVN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Longeveron →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.